血清和支气管肺泡灌洗液GM试验对非粒细胞缺乏患者不同类型肺曲霉病的诊断价值分析

中国真菌学杂志　 2022, Vol. 17 　Issue (2): 146-151.

血清和支气管肺泡灌洗液GM试验对非粒细胞缺乏患者不同类型肺曲霉病的诊断价值分析

张传明, 曹泓宇, 孙继德, 牛司强, 王詝, 蒲姝丽, 徐绣宇

重庆医科大学附属第一医院检验科, 重庆 400016

收稿日期:2021-05-13 出版日期:2022-04-28 发布日期:2022-05-07
通讯作者: 徐绣宇,E-mail:xuxiuyu85@126.com E-mail:xuxiuyu85@126.com
作者简介:张传明,男(汉族),硕士,初级技师.E-mail:zhangchuanming2012@126.com

Diagnostic value of serum and bronchoalveolar lavage fluid galactomannan test in non-neutropenic patients with different types of pulmonary aspergillosis

ZHANG Chuanming, CAO Hongyu, SUN Jide, NIU Siqiang, WANG Zhu, PU Shuli, XU Xiuyu

The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China

Received:2021-05-13 Online:2022-04-28 Published:2022-05-07

摘要/Abstract

摘要： 目的探讨血清和支气管肺泡灌洗液（BALF）GM试验在不同类型肺曲霉病中的诊断价值，并确定BALF GM试验对常见肺曲霉病的最优cut-off值。方法收集2017年1月至2021年3月在重庆医科大学附属第一医院诊断为肺曲霉病且同时送检过血清和BALF GM试验的非粒细胞缺乏患者资料146例，其中侵袭性肺曲霉病（invasive pulmonary aspergillosis， IPA）97例，慢性肺曲霉病（chronic pulmonary aspergillosis， CPA）39例，变应性支气管肺曲霉病（allergic bronchopulmonary aspergillosis， ABPA） 10例;并随机选取132例同时期患有其他类型肺部疾病者作为对照组。统计分析血清和BALF GM试验对不同类型肺曲霉病的诊断性能。结果在非粒细胞缺乏患者中，BALF GM试验对IPA和CPA诊断的最优cut-off值分别为1.0和0.91，敏感性分别为74.2%和74.4%，特异性分别为83.3%和81.1%，但对ABPA的诊断作用有限（AUC=0.648）;在cut-off值为0.5时，血清GM试验对IPA和CPA的诊断敏感性分别为41.2%和10.3%，对ABPA的诊断价值较差（AUC<0.5）。结论在非粒细胞缺乏患者中，BALF GM试验对IPA和CPA的诊断均有良好辅助诊断作用，但对ABPA的诊断作用有限;血清GM试验对IPA和CPA的诊断敏感性较低，对ABPA的诊断价值更差。

关键词: 肺曲霉病, 支气管肺泡灌洗液, GM试验, 诊断价值

Abstract: Objective To investigate the diagnostic value of serum and bronchoalveolar lavage fluid (BALF) galactomannan (GM) test in different types of pulmonary aspergillosis, and to determine the best cut-off value of BALF GM test for different pulmonary aspergillosis. Methods From January 2017 to March 2021, clinical data of 146 non-neutropenic patients diagnosed with pulmonary aspergillosis who underwent serum and BALF GM test in the First Affiliated Hospital of Chongqing Medical University were collected, including 97 cases of IPA, 39 cases of CPA and 10 cases of ABPA. 132 patients with other lung diseases in the same period were randomly selected as the control group. The diagnostic performance of serum and BALF GM test for different types of pulmonary aspergillosis was analyzed. Results In non-neutropenic patients, the best cut-off values of BALF GM test for IPA and CPA were 1.0 and 0.91, the sensitivity were 74.2% and 74.4%, and the specificity were 83.3% and 81.1%, respectively. However, the diagnostic value of BALF GM test for ABPA was limited (AUC=0.648). At a cut-off value of 0.5, the diagnostic sensitivity of serum GM test for IPA and CPA was 41.2% and 10.3%, respectively, and the diagnostic value for ABPA was even worse (AUC<0.5). Conclusion In non-neutropenic patients, BALF GM test has a good diagnostic effect on IPA and CPA, but its diagnostic effect on ABPA is limited. The diagnostic sensitivity of serum GM test to IPA and CPA is low, and its diagnostic value of ABPA is worse.

Key words: pulmonary aspergillosis, bronchoalveolar lavage fluid, galactomannan test, diagnostic value

中图分类号:

R519.8
R563

张传明, 曹泓宇, 孙继德, 牛司强, 王詝, 蒲姝丽, 徐绣宇. 血清和支气管肺泡灌洗液GM试验对非粒细胞缺乏患者不同类型肺曲霉病的诊断价值分析[J]. 中国真菌学杂志, 2022, 17(2): 146-151.

ZHANG Chuanming, CAO Hongyu, SUN Jide, NIU Siqiang, WANG Zhu, PU Shuli, XU Xiuyu. Diagnostic value of serum and bronchoalveolar lavage fluid galactomannan test in non-neutropenic patients with different types of pulmonary aspergillosis[J]. Chinese Journal of Mycology, 2022, 17(2): 146-151.

参考文献

[1] EL-BABA F, GAO Y, SOUBANI A O. Pulmonary aspergillosis:What the generalist needs to know[J]. Am J Med, 2020, 133(6):668-674.
[2] KANJ A, ABDALLAH N, SOUBANI A O.The spectrum of pulmonary aspergillosis[J]. Respir Med, 2018, 141:121-131.DOI:10.1016/j.rmed.2018.06.029.
[3] SEHGAL IS, DHOORIA S, CHOUDHARY H,et al. Utility of serum and bronchoalveolar lavage fluid galactomannan in diagnosis of chronic pulmonary aspergillosis[J]. J Clin Microbiol, 2019, 57(3):e01821-18.
[4] DONNELLY J P, CHEN S C, KAUFFMAN C A,et al. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium[J]. Clin Infect Dis, 2020, 71(6):1367-1376.
[5] DENNING D W, CADRANEL J, BEIGELMAN-AUBRY C, et al. Chronic pulmonary aspergillosis:rationale and clinical guidelines for diagnosis and management[J]. Eur Respir J, 2016, 47(1):45-68.
[6] WALSH T J, ANAISSIE E J, DENNING D W, et al. Treatment of aspergillosis:clinical practice guidelines of the Infectious Diseases Society of America[J]. Clin Infect Dis, 2008, 46(3):327-360.
[7] 王杰, 杨青, 黄怡. 肺部感染性疾病支气管肺泡灌洗病原体检测中国专家共识(2017年版)[J]. 中华结核和呼吸杂志, 2017, 40(8):578-583.
[8] HAYDOUR Q, HAGE C A, CARMONA E M,et al. Diagnosis of fungal infections. a systematic review and meta-analysis supporting American Thoracic Society practice guideline[J]. Ann Am Thorac Soc, 2019, 16(9):1179-1188.
[9] ZHOU W, LI H, ZHANG Y, et al. Diagnostic value of galactomannan antigen test in serum and bronchoalveolar lavage fluid samples from patients with nonneutropenic invasive pulmonary aspergillosis[J]. J Clin Microbiol, 2017, 55(7):2153-2161.
[10] LI H, RUI Y, ZHOU W, et al. Role of the Aspergillus-specific IgG and IgM test in the diagnosis and follow-up of chronic pulmonary aspergillosis[J]. Front Microbiol, 2019, 10:1438.DOI:10.3389/fmicb.2019.01438.
[11] TAKAZONO T, ITO Y, TASHIRO M, et al. Evaluation of Aspergillus-specific lateral-flow device test using serum and bronchoalveolar lavage fluid for diagnosis of chronic pulmonary aspergillosis[J]. J Clin Microbiol, 2019, 57(5):e00095-19.
[12] URABE N, SAKAMOTO S, SANO G,et al. Usefulness of two Aspergillus PCR assays and Aspergillus galactomannan and β-D-glucan testing of bronchoalveolar lavage fluid for diagnosis of chronic pulmonary aspergillosis[J]. J Clin Microbiol, 2017, 55(6):1738-1746.
[13] JHUN B W, JEON K, EOM J S,et al. Clinical characteristics and treatment outcomes of chronic pulmonary aspergillosis[J]. Med Mycol, 2013, 51(8):811-817.
[14] 苏铎华, 汤春梅, 邝浩斌, 等. 支气管肺泡灌洗液GM试验对慢性肺曲霉病的早期诊断及疗效评估价值[J]. 临床肺科杂志, 2020, 25(8):1140-1144.
[15] SHAH A, PANJABI C. Allergic bronchopulmonary aspergillosis:a perplexing clinical entity[J]. Allergy Asthma Immunol Res, 2016, 8(4):282-297.
[16] AGARWAL R, MASKEY D, AGGARWAL A N, et al. Diagnostic performance of various tests and criteria employed in allergic bronchopulmonary aspergillosis:a latent class analysis[J]. PLoS One, 2013, 8(4):e61105.
[17] AGARWAL R, AGGARWAL A N, SEHGAL I S, et al. Performance of serum galactomannan in patients with allergic bronchopulmonary aspergillosis[J]. Mycoses, 2015, 58(7):408-412.